Iulian Pruteanu-Malinici

1 ta ish

Novartis (United States)

1. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

   Joseph A. Fraietta, Simon F. Lacey, Elena J. Orlando +34

   MaqolaOAOchiq kirish20182 iqtibos

   ABIABI:AkademIndex/2026.other.020493